Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) E10: $0.10 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:T14 Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SGX:T14
66 GF Score
Price $2.65
GF Value $1.64
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group E10?

Tianjin Pharmaceutical Da Ren Tang Group SGX:T14 -1.85% 66 E10 is $0.10 as of Jun. 2026. GuruFocus rates SGX:T14 with a GF Score™ of 66/100 and a GF Value™ of $1.64 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Tianjin Pharmaceutical Da Ren Tang Group's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.043. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.10 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Tianjin Pharmaceutical Da Ren Tang Group's average E10 Growth Rate was 3.80% per year. During the past 3 years, the average E10 Growth Rate was 18.60% per year. During the past 5 years, the average E10 Growth Rate was 13.70% per year. During the past 10 years, the average E10 Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Tianjin Pharmaceutical Da Ren Tang Group was 34.70% per year. The lowest was 6.80% per year. And the median was 16.25% per year.

As of today (2026-08-16), Tianjin Pharmaceutical Da Ren Tang Group's current stock price is $2.65. Tianjin Pharmaceutical Da Ren Tang Group's E10 for the quarter that ended in Jun. 2026 was $0.10. Tianjin Pharmaceutical Da Ren Tang Group's Shiller PE Ratio of today is 26.50.

During the past 13 years, the highest Shiller PE Ratio of Tianjin Pharmaceutical Da Ren Tang Group was 68.27. The lowest was 19.34. And the median was 32.84.


Tianjin Pharmaceutical Da Ren Tang Group  (SGX:T14) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Tianjin Pharmaceutical Da Ren Tang Group's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=2.65/0.10
=26.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Tianjin Pharmaceutical Da Ren Tang Group was 68.27. The lowest was 19.34. And the median was 32.84.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Tianjin Pharmaceutical Da Ren Tang Group E10 Related Terms


Tianjin Pharmaceutical Da Ren Tang Group E10 Historical Data

* Premium members only.

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group E10 Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.05 0.08 0.10

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.09 0.10 0.11 0.10

SGX:T14 vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Shiller PE Ratio falls into.


SGX:T14
66GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SGX:T14
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianjin Pharmaceutical Da Ren Tang Group E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tianjin Pharmaceutical Da Ren Tang Group's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.043/116.0564*116.0564
=0.043

Current CPI (Jun. 2026) = 116.0564.

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data

per share eps CPI Adj_EPS
201609 0.018 102.400 0.020
201612 0.013 102.600 0.015
201703 0.025 103.200 0.028
201706 0.028 103.100 0.032
201709 0.017 104.100 0.019
201712 0.023 104.500 0.026
201803 0.036 105.300 0.040
201806 0.028 104.900 0.031
201809 0.016 106.600 0.017
201812 0.030 106.500 0.033
201903 0.037 107.700 0.040
201906 0.029 107.700 0.031
201909 0.018 109.800 0.019
201912 0.033 111.200 0.034
202003 0.031 112.300 0.032
202006 0.028 110.400 0.029
202009 0.029 111.700 0.030
202012 0.037 111.500 0.039
202103 0.043 112.662 0.044
202106 0.050 111.769 0.052
202109 0.040 112.215 0.041
202112 0.022 113.108 0.023
202203 0.041 114.335 0.042
202206 0.052 114.558 0.053
202209 0.047 115.339 0.047
202212 0.024 115.116 0.024
202303 0.075 115.116 0.076
202306 0.059 114.558 0.060
202309 0.023 115.339 0.023
202312 0.024 114.781 0.024
202403 0.069 115.227 0.069
202406 0.048 114.781 0.049
202409 0.027 115.785 0.027
202412 0.254 114.893 0.257
202503 0.068 115.116 0.069
202506 0.280 114.907 0.283
202509 0.042 115.471 0.042
202512 -0.004 115.832 -0.004
202603 0.080 116.303 0.080
202606 0.043 116.056 0.043

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.10 mean?
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) has a E10 of $0.10 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors.
Is Tianjin Pharmaceutical Da Ren Tang Group's E10 too high?
Tianjin Pharmaceutical Da Ren Tang Group's current E10 is $0.10. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's E10 compare to ZTS?
Tianjin Pharmaceutical Da Ren Tang Group's E10 of $0.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. Tianjin Pharmaceutical Da Ren Tang Group's current E10 is $0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.64, compared to a current price of $2.65 — trading 61.6% above its estimated fair value. The current E10 is $0.10. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14), the current E10 is $0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of $2.65 is trading 61.6% above its estimated GF Value™ of $1.64. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for SGX:T14:

  • E10: $0.10
  • GF Value™: $1.64 vs. price of $2.65 (61.6% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the SGX:T14 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges 2TZ:Germany600329:China
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
66GF Score

Get the complete analysis for SGX:T14

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$1.64
GF Value